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Abstract: Vasomotor symptoms (VMS), including hot flashes and night sweats, occur in as 
many as 68.5% of women as a result of menopause. While the median duration of these symptoms 
is 4 years, approximately 10% of women continue to experience VMS as many as 12 years 
after their final menstrual period. As such, VMS have a significant impact on the quality of 
life and overall physical health of women experiencing VMS, leading to their pursuance of 
treatment to alleviate these symptoms. Management of VMS includes lifestyle modifications, 
some herbal and vitamin supplements, hormonal therapies including estrogen and tibolone, 
and nonhormonal therapies including clonidine, gabapentin, and some of the serotonin and 
serotonin–norepinephrine reuptake inhibitors. The latter agents, including desvenlafaxine, have 
been the focus of increased research as more is discovered about the roles of serotonin and 
norepinephrine in the thermoregulatory control system. This review will include an overview 
of VMS as they relate to menopause. It will discuss the risk factors for VMS as well as the 
proposed pathophysiology behind their occurrence. The variety of treatment options for VMS 
will be discussed. Focus will be given to the role of desvenlafaxine as a treatment option for 
VMS management.
Keywords: menopause, vasomotor symptoms, hot flashes, vasomotor symptom treatment, 
desvenlafaxine
Introduction
The final menstrual period (FMP) marks the point in time between the menopausal 
transition and postmenopause.1 Natural menopause, specifically, is confirmed after 12 
consecutive months of amenorrhea in the absence of any obvious, pathologic cause.2 
These 12 months of amenorrhea, inclusive, characterize a woman as postmenopausal.1 
This can further be divided into early postmenopause (1–4 years after the FMP) and 
late postmenopause (.5 years since the FMP).1,3 Surgical menopause results following 
surgical removal of the ovaries. In either instance, one result of the declining estrogen 
concentrations is the occurrence of vasomotor symptoms (VMS) that include hot 
flashes and night sweats.
VMS of any degree, mild to severe, are experienced by 58.9% of Latin American 
women at perimenopause, the years immediately surrounding the FMP.3 The peak 
incidence of VMS is noted to occur in American women 1 year after the FMP,4 and 
68.5% of women experience VMS of some degree in early menopause, which is 
described as 1–5 years after the FMP.3 Further, the median duration of VMS occurrence 
is 4 years, while approximately 10% of women experience VMS as long as 12 years 
after the FMP.4
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Severe VMS occurs in 10.8% of women in the 
perimenopausal time frame, in 12.3% of women during 
early menopause, and in 11.5% of women in late menopause, 
def ined as greater than 5 years from the FMP.3 The 
prevalence and severity of VMS is greater in women who 
are surgically menopausal compared to women experiencing 
natural menopause.3 Given the overall frequency of these 
symptoms, it is important to be aware of the risk factors for 
their occurrence such that if the risk factor(s) are modifiable, 
the risk of VMS could be reduced. Further, awareness of risk 
may help to identify those women who may be in greatest 
need of VMS treatment as a means to improve quality of life 
(QOL) and overall health.
VMS risk factors
Several risk factors for the occurrence and severity of VMS 
have been established.5–7 Obesity, race, and smoking have 
been most closely associated with the occurrence of VMS. 
Various reports of the linkage between obesity and VMS 
include the fact that VMS were observed to be absent or 
infrequent in a population of women with a mean body mass 
index (BMI) of 28 kg/m2 while women with an average BMI 
of 31 kg/m2 were more likely to report VMS as occurring 
more frequently than their lower-BMI counterparts.5 
Further, Gold and colleagues discovered similar findings 
as the frequency of VMS was statistically associated with 
the woman’s BMI (P , 0.0001); the average BMI for 
women experiencing no VMS or symptoms for ,6 days 
in the 2 weeks prior to evaluation was 28 kg/m2, while the 
average BMI for women experiencing VMS $ 6 days in 
the prior 2 weeks was 30.9 kg/m.2,6 Specifically, another 
study established a sevenfold greater risk for being in the 
highest quartile of having the most bothersome VMS for 
every 2.7 kg/m2 increase in BMI.7 While the physiologic 
relationship between BMI and VMS frequency and severity 
is not completely understood, it is thought to be linked to 
the role of adipose tissue as an insulator that prevents the 
release of heat.5
Race and ethnic variations are also associated with 
differences in the incidence of VMS. One study established 
that the frequency of VMS is significantly greater among 
African American women compared to women of other races 
(P , 0.01).6 While the exact reason for this is unknown, this 
population of women has been observed to have the highest 
BMIs and highest rates of current smoking and exposure to 
tobacco smoke. Further, African American women have been 
observed to exhibit a different perception and tolerance 
of VMS compared to other racial and ethnic populations. 
Another study confirmed this finding in African American 
women when it reported that they are most likely to report 
and describe their VMS as bothersome.5 Caucasian and 
Hispanic women report VMS as often as African American 
women, but do not report them to be as severe. Chinese and 
Japanese women are the least likely to report VMS or to 
describe them as bothersome.5 Overall, variability among 
different cultures may be related to variability (by culture) 
of other determinants of VMS, such as hormone use, age, 
BMI, depression, anxiety, poor physical health, perceived 
stress, cigarette smoking (and exposure to passive smoke), 
and acculturation.8
A link between cigarette smoking as well as passive 
exposure to tobacco smoke and the occurrence of VMS has 
been hypothesized to exist, as cigarette smoking may exhibit 
antiestrogenic effects. Study findings have illustrated that 
smokers are 60% more likely to report any VMS compared 
to nonsmokers.5 Additionally, the frequency of VMS is 
associated with current smoking; the odds ratio for smokers 
reporting VMS being 1.63 (range 1.25–2.12; P , 0.01) 
compared to nonsmokers.6
Other risk factors for VMS that have been identified but 
for which the data are limited include physical inactivity, 
the presence of negative affect or anxiety, and educational 
status. The associations between physical inactivity and VMS 
have been studied and described as weak.5 While anxiety and 
negative affect have been associated with VMS occurrence 
and frequency as well as an increased likelihood of the VMS 
being described as bothersome,5 these findings have not 
been studied extensively. In fact, it is difficult to reach any 
conclusion using the available studies that would be applicable 
to practice, as the studies utilized poor, largely nonvalidated 
measures of said symptoms.9 Similarly, an association 
between VMS and level of education has been observed. 
VMS reports have been observed to be higher among women 
with some college education compared to women with high 
school as their terminal level of education increases.6 This 
has not been replicated or reported elsewhere.
Impact of VMS on quality of life
VMS negatively affect QOL,3,5 and this has been evaluated 
globally as well as specifically for its impact on the factors 
contributing to QOL. These factors include sexual function, 
sleep quality, mood, and cognitive function.
The poorest health-related QOL has been observed among 
women with the most frequent VMS.5 More precisely, when 
comparing women who experience VMS to those in whom 
VMS are absent, any degree of VMS is associated with 
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nearly a fivefold higher risk for severe QOL impairment; 
severe VMS are associated with a 20-fold higher risk for 
severe QOL impairment (P = 0.0001 for both compared to 
absent VMS).3 Women experiencing any degree of VMS 
are at an increased risk of experiencing other menopausal 
symptoms when compared to women who do not have VMS. 
Specifically, in women who experience VMS, 62% of them 
also experience sexual disturbances, 74% suffer from sleep 
disturbances, 76% note the occurrence of depressed mood, 
and 78% experience increased mental exhaustion. These 
menopausal symptoms occur in 29%, 41%, 42%, and 49% 
of women without VMS, respectively.3 Further, Thurston and 
Joffe’s findings also concluded that the presence of VMS is 
associated with all aspects of sleep disturbances including 
poor continuity and quality and early morning awakening.5
VMS pathophysiology
VMS are theorized to result from dysfunction in the woman’s 
“tightly controlled temperature circuitry,” leading to 
exaggerated activation of heat-dissipation responses such as 
peripheral vasodilation and sweating.10 The thermoregulatory 
circuitry includes the brain, internal body cavity, and the 
peripheral vasculature. It is thought that this circuitry 
functions under the influence of consistent concentrations of 
the neurotransmitters serotonin and norepinephrine.
Changes in gonadal hormones, notably estrogen, 
have been associated with fluctuations in serotonin and 
norepinephrine. The occurrence of VMS with the fluctuating 
levels of estrogen observed during perimenopause and the 
further declining levels of estrogen as occurs after menopause 
is likely influenced by the resultant fluctuating levels of 
serotonin and norepinephrine, contributing to disruption of the 
thermoregulatory circuitry.10 Specifically, reduced estrogen 
concentrations within the hypothalamic temperatures center 
negatively affect serotonin and norepinephrine concentrations 
in this location and contribute significantly to the occurrence 
of VMS.11 Temperature information is processed within the 
anterior hypothalamus in the preoptic area (POA), where it 
is felt that heat-sensitive neurons control the release of heat.11 
Serotonergic neurons and noradrenergic pathways have both 
been identified as projecting into the POA. As the POA is 
directly related to temperature control and under the influence 
of serotonin and norepinephrine, the fluctuating estrogen 
concentrations that exist with menopause lead to VMS.
Given the data linking estrogen fluctuations to a reduction 
of serotonin and norepinephrine, it has been postulated that 
pharmacologic agents such as serotonin reuptake inhibitors 
and serotonin–norepinephrine reuptake inhibitors may help 
to reestablish levels of these neurochemicals within the ther-
moregulatory centers, reducing the occurrence of VMS.10,11
VMS treatment
Nonpharmacologic
Many nonpharmacologic treatments have been identified to 
treat VMS. These include but are not limited to acupunc-
ture, hypnosis, and lifestyle changes. The overall evidence 
supporting these treatments is variable. See Table 1 for a 
list of potential nonpharmacologic treatment options and a 
summary of the evidence available for each.
Pharmacologic
Herbals/vitamins
A variety of herbal medications and vitamin supplements 
have been studied for the treatment of VMS associated with 
menopause, including black cohosh, dehydroepiandrosterone, 
evening primrose oil, phytoestrogens, and vitamin E.  Similar 
to the findings for the nonpharmacologic interventions for 
VMS, the efficacy findings for herbal medications and 
Table 1 Nonpharmacologic treatments for vasomotor symptoms (vMS)12–18
Nonpharmacologic 
treatment
Evidence
Acupuncture •  A randomized clinical trial illustrated that acupuncture was as effective as venlafaxine at reducing hot flushes.12 
•   Another study and review have shown a significant reduction in the mean number of hot flushes with acupuncture 
compared to placebo.13,14
Hypnosis •  Two small studies in breast cancer patients showed that hypnosis was more effective at reducing vasomotor 
symptoms (vMS) compared to no treatment.15,16
Lifestyle changes 
• Layered clothing 
• Cool atmosphere 
• Cool drinks 
• Avoiding hot/spicy food 
• Exercise/weight loss 
• Smoking cessation
•  Studies have shown that keeping cool by using layered clothing, cooler room temperatures, drinking cool liquids, and 
avoiding triggers such as hot/spicy food can help with the severity of hot flushes.17
•   Studies regarding the efficacy of exercise in relieving VMS are ongoing;18 however, at this time there is an overall 
lack of randomized controlled clinical trials.
• Clinical trials evaluating the effect of weight loss on vMS are lacking. 
•  Many researchers believe smoking cessation can help reduce vasomotor symptoms, although evidence in this area is 
lacking, as there are currently no clinical trials evaluating this idea.
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Table 2 Herbals and vitamins for the treatment of vasomotor symptoms (vMS)20–35
Herbal/vitamin Efficacy/safety information
Black cohosh •  Two meta-analyses showed black cohosh to have some benefit in treating VMS.20,21 
•   One randomized trial showed black cohosh to have similar efficacy to tibolone at reducing VMS, as 
measured by the Kupperman Menopause Index.22
•   One meta-analysis and another randomized controlled trial have shown no benefit to treatment with 
black cohosh.22,24
•  Long-term effects are unknown, and there exists a possibility of hepatotoxicity.20,21 However, a recent 
meta-analysis of five studies (two had a duration of 12 weeks, two had a duration of 16 weeks, and one 
had a duration of 24 weeks) showed that black cohosh does not negatively impact liver function.25
•  The overall long-term efficacy and safety data for black cohosh remain unclear.
Black cohosh with St John’s wort •   A randomized controlled trial showed that the combination of these herbals significantly improved VMS 
and symptoms of depression as measured by the Menopause Rating Scale and Hamilton Depression 
Rating Scale, respectively, compared with placebo.26
Dehydroepiandrosterone (DHEA) •   A small study has shown a reduction in the frequency of hot flushes in patients taking DHEA supplements.27
•  Larger randomized trials are needed to further evaluate these findings.
Evening primrose oil •  Randomized trials have not shown any benefit in the frequency of hot flushes with evening primrose oil.28
Phytoestrogens 
•  Isoflavones 
• Soy 
• Red clover 
• Lignan
• One clinical trial and two meta-analyses do not support the use of soy for vasomotor symptoms.29–31 
•   A very recent meta-analysis of 17 trials found soy isoflavone supplements to be significantly more 
effective than placebo at reducing the frequency and severity of hot flashes.32
•  A recent meta-analysis and randomized clinical trial concluded there was no impact on the incidence and 
severity of hot flushes with red clover.30,33
•   Flaxseed, which is very high in lignan, has been studied for the treatment of hot flushes and has been 
shown to successfully reduce vMS.34
vitamin E •   A randomized clinical trial showed that Vitamin E reduced the occurrence of hot flashes by about one 
per day;35 however, it was not preferred by patients over placebo.
•  Not recommended at this time due to clinically insignificant effects.
vitamin supplements are also inconsistent.19 Further, the long-
term safety of these products is unclear.19 Table 2 depicts 
the various herbal medications and vitamins that have been 
examined for menopausal-related VMS, including a review 
of the efficacy and safety information available for each.
Hormone therapy
Estrogen replacement
Hormone replacement therapy remains the most effective 
treatment for VMS. According to the most recent Cochrane 
review, hormone therapy reduces the frequency and severity 
of hot flashes by 75%–79%.36 There are numerous estrogen 
and estrogen–progestin combination products available for 
women to use. Studies have shown hormone therapy to be 
well tolerated, with the most common side effects including 
breast tenderness, headache, and uterine bleeding.
Although hormone therapy is effective for the treat-
ment of VMS, results from the Women’s Health Initiative 
(WHI) demonstrate that hormone replacement therapy may 
have negative effects on breast tissue, as its use has been 
associated with an increased risk of breast cancer.37 The 
WHI also shows that unopposed estrogen therapy is asso-
ciated with an increased risk of endometrial cancer.37 The 
WHI has also shown that hormone replacement therapy is 
associated with an increased risk of cardiovascular disease. 
Since the WHI report, women have become more appre-
hensive regarding the use of hormone replacement therapy 
due to these safety concerns. Current recommendations are 
to use hormone replacement therapy at the lowest effective 
dose for the shortest duration of time.2 Because of these 
findings and the reaction of women towards them, there 
has been increased demand for alternative medications to 
treat VMS.
Tibolone
Tibolone is another option for the treatment of VMS. It is 
available in Europe, Canada, and some other countries in 
Latin America and Asia; it is not approved in the United 
States. Tibolone is a synthetic drug, and its metabolites have 
properties similar to estrogen, androgen, and progesterone.38 
Compared to hormone replacement therapy, studies have 
found that there is a lower incidence of uterine bleeding 
with tibolone.38 Relative to VMS, most studies show that its 
efficacy is comparable to hormone replacement therapy.39 
However, its use carries similar risks to hormone replacement 
therapy in breast and endometrial tissues. A number of studies 
have indicated that tibolone may increase the risk of breast 
cancer and endometrial hyperplasia.38,40,41 For these reasons, 
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tibolone may not be any safer than hormone replacement 
therapy itself.
Tissue-selective estrogen complexes
A new hormone therapy being developed in the US is tissue-
selective estrogen complexes. This therapy combines a 
selective estrogen receptor modulator (SERM) with estrogen. 
SERMs act as agonists or antagonists in different tissues, 
and each SERM has a distinct profile of action. With the 
appropriate SERM in place, estrogen’s negative effects are 
blocked in breast and endometrial tissues. This allows the 
estrogen to impart its positive effects on bone and vaginal 
tissue as well as reduce VMS.42
Currently, the SERM bazedoxifene, which is an 
agonist in the bone and an antagonist in the breast and 
uterus, is being studied in combination with estrogen for 
the treatment of menopausal symptoms. The Phase III 
SMART-1 (Selective estrogens, Menopause and Response 
to Therapy) trial demonstrated that the combination of 
estrogen and bazedoxifene significantly reduces hot flashes 
at most time points, with higher doses of bazedoxifene being 
more effective.43 The results also show that there is a very 
low incidence of endometrial hyperplasia after 2 years of 
treatment. More randomized controlled trials are underway 
to assess the long-term effect of this combination therapy on 
the bone and breast. Nevertheless, tissue-selective estrogen 
complexes have the possibility of providing comparable 
efficacy to hormone replacement therapy with an improved 
safety and tolerability profile.
Nonhormone therapies
Clonidine
A number of double-blind, controlled trials have evaluated 
the efficacy of clonidine for VMS.44,45 One trial studied 
the clonidine patch versus placebo in 110 women with a 
history of breast cancer and found that clonidine reduces the 
frequency of hot flashes by 20% at 4 weeks (P , 0.001).44 
Another study evaluated 149 postmenopausal women over 
8 weeks and found a decrease in hot-flash frequency of 38% 
in the clonidine group versus a 24% reduction in placebo 
(P = 0.006).45 Both of these trials did show that clonidine is 
associated with considerable adverse effects, including dry 
mouth, constipation, and drowsiness.44,45 Based on a recent 
meta-analysis, the results of these trials have been rather 
inconsistent regarding the efficacy of clonidine in VMS.30 
Half of the trials included in this meta-analysis show that 
clonidine significantly reduces VMS frequency compared to 
placebo, while the other half of the trials show no significant 
difference. With its inconsistent efficacy data and substantial 
adverse effects, clonidine is not an ideal choice for VMS 
treatment.
Gabapentin
Multiple randomized controlled trials evaluating the efficacy 
of gabapentin for the treatment of VMS show that gabapentin 
can successfully reduce VMS frequency compared to 
placebo.46,47 One trial involving 59 postmenopausal women 
compared 900 mg/day gabapentin versus placebo and 
found a 45% reduction in the gabapentin group versus 
29% in the placebo group at week 12 (P = 0.02).46 A larger 
trial involving 420 women with breast cancer evaluated 
gabapentin 300 mg/day, 900 mg/day, and placebo.47 The 
study showed a 49% reduction in hot-flash severity scores at 
week 8 in the 900-mg group, a 33% reduction in the 300-mg 
group, and a 21% reduction in the placebo group (P = 0.007 
for all comparisons).47 A randomized control trial of 
60 postmenopausal women comparing gabapentin titrated up 
to 2400 mg/day, estrogen therapy, and placebo showed that 
gabapentin reduced the frequency of VMS by 71%, compared 
to 72% in the estrogen group and 54% in the placebo group 
at week 12 (P = 0.04 for gabapentin compared to placebo; 
no significant difference between gabapentin and estrogen).48 
Larger and longer trials are warranted to further examine the 
efficacy and safety of gabapentin for treating VMS.
Pregabalin
Pregabalin is currently indicated for the treatment of fibro-
myalgia, partial-onset seizures, postherpetic neuralgia, and 
pain associated with diabetic neuropathy. Chemically, it is 
similar to gabapentin, and for that reason, its use in treating 
VMS is being evaluated.49 Results of a Phase III randomized 
trial involving 163 postmenopausal women over 6 weeks 
demonstrated that pregabalin at doses of 75 mg twice daily 
and 150 mg twice daily reduced hot-flash scores by 65% 
and 71%, respectively, compared to only 50% in the placebo 
group (P = 0.009 and P = 0.007, respectively).50 Larger, 
longer-term trials are needed to confirm these results.
Selective serotonin reuptake inhibitors/
serotonin–norepinephrine reuptake 
inhibitors
The selective serotonin reuptake inhibitors (SSRIs), such 
as citalopram, escitalopram, fluoxetine, paroxetine, and 
sertraline, and the serotonin–norepinephrine reuptake 
inhibitors (SNRIs), such as duloxetine, venlafaxine, 
and desvenlafaxine, have been investigated for the 
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treatment of VMS. Two randomized controlled trials have 
shown that paroxetine reduces symptoms of VMS.51,52 In 
one study, 156 menopausal women received paroxetine 
12.5 mg/day, 25 mg/day, or placebo. The study demonstrated 
a 62% reduction in hot-flash score at 6 weeks in the 12.5-mg 
group, a 65% reduction in the 25-mg group, and a 38% reduc-
tion in the placebo group (P = 0.03 and P = 0.007 vs placebo, 
respectively).51 In another study, 151 postmenopausal women 
received 4 weeks of paroxetine 10 mg/day, paroxetine 
20 mg/day, or placebo. Results showed the 10-mg group 
reduced the hot-flash severity score by 40.6% compared to 
the 13.7% reduction in the placebo group (P = 0.006), while 
the 20-mg group reduced hot-flash severity score by 51.7%, 
compared to 26.6% for the placebo comparator (P = 0.002).52 
 Randomized trials have shown that citalopram, escitalopram, 
and fluoxetine are also effective at reducing the frequency of 
hot flashes. In a trial evaluating citalopram, 254 postmeno-
pausal women received citalopram 10 mg/day, citalopram 
20 mg/day, citalopram 30 mg/day, or placebo.53 After 
6 weeks, there was a mean reduction in hot-flash severity 
score of 49% in the 10-mg group, 50% in the 20-mg group, 
and 55% in the 30-mg group compared to 23% in the placebo 
group (P , 0.002 for all comparisons).53 A recent randomized 
double-blind placebo-controlled trial evaluated escitalopram 
for vasomotor symptoms. The trial enrolled 205 post-
menopausal women that were randomized to escitalopram 
10–20 mg/day or placebo for 8 weeks. The results showed 
women in the escitalopram group experienced a significant 
reduction in hot-flash frequency (P , 0.001) and hot-flash 
severity score (P , 0.001).54 In a trial studying fluoxetine, 
81 postmenopausal women were randomized to fluoxetine 
20 mg/day or placebo for 4 weeks and then crossed over to the 
other treatment arm.55 In the first part of the trial, the 20-mg 
group reduced hot-flash scores by 50% compared to only 
36% in the placebo group (P = 0.35), but after the crossover 
the reduction in hot flash scores was significant (24% vs 
19%, respectively, P = 0.02).55 Other trials have evaluated 
the efficacy of sertraline for the treatment of vasomotor 
symptoms. In one double-blind crossover study evaluating 
sertraline, 62 breast cancer survivors receiving tamoxifen 
were randomized to 50 mg sertraline or placebo.56 The results 
showed women taking sertraline for 6 weeks had a significant 
reduction in hot-flash score compared to placebo (P = 0.03).56 
Another double-blind crossover study of 102 women found 
that women experienced five fewer hot flashes per week while 
taking sertraline 50 mg versus placebo (P , 0.002); however, 
the severity of the hot flashes was not significantly different 
between sertraline and placebo.57 Most of the trials evaluating 
SSRIs have been relatively small and short in duration, and 
larger and longer trials are warranted. Overall, SSRIs appear 
to be effective in reducing VMS.
One very small trial has evaluated the SNRI duloxetine with 
favorable outcomes. In an open-label trial, 20 postmenopausal 
women with major depressive disorder were given duloxetine 
at 60–120 mg/day. At the end of 8 weeks, the women showed 
a significant improvement in the Montgomery–Asberg 
Depression Rating Scale score from baseline (P , 0.001).58 
Trials evaluating the SNRI venlafaxine for VMS have yielded 
positive results, showing an approximate 55% reduction 
in VMS.59,60 In one study, 191 postmenopausal women 
were assigned to placebo or to target venlafaxine doses of 
37.5 mg/day, 75 mg/day, or 150 mg/day. Hot-flash scores 
reduced from baseline by 27% in the placebo group, 37% in 
the 37.5-mg group, 61% in the 75-mg group, and 61% in the 
150-mg group after 4 weeks (P , 0.0001 for all comparisons 
vs placebo).59 This study demonstrated that higher doses 
of venlafaxine did not correlate with improved efficacy; 
however, the 150-mg dose had significantly more side effects 
compared to placebo (P , 0.05), including dry mouth, 
decreased appetite, nausea, and constipation.59 Another 
trial of 109 postmenopausal women compared venlafaxine 
at a dose of 75 mg/day to a single injection of 400 mg of 
depomedroxyprogesterone acetate (DMPA).60 There was a 
55% reduction in hot-flash score in the venlafaxine group, 
versus a 79% reduction in the DMPA group after 6 weeks 
of treatment (P , 0.001).60 Although venlafaxine does not 
appear to be superior to hormone replacement therapy, 
it is still a good option for the treatment of vasomotor 
symptoms.
Desvenlafaxine is the major active metabolite of venla-
faxine, and therefore it has been postulated that desvenlafax-
ine may be effective at reducing VMS frequency and severity. 
In a study that evaluated the effects of desvenlafaxine on 
temperature regulation in ovariectomized rats, desvenla-
faxine significantly increased serotonin and norepinephrine 
levels in areas of the hypothalamus that are important for 
temperature homeostasis.61 Therefore, it is hypothesized that 
desvenlafaxine would be effective in treating VMS caused by 
temperature dysregulation in the hypothalamus, specifically 
for VMS associated with menopause.
Desvenlafaxine clinical trials
To date, four clinical trials have evaluated desvenlafaxine’s 
efficacy in treating VMS in postmenopausal women.62–65 In 
Speroff and colleagues, 707 postmenopausal women were 
assigned to desvenlafaxine 50, 100, 150, or 200 mg/day 
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or placebo and evaluated over 12 weeks.62 In one trial 
by Archer and colleagues, 484 postmenopausal women 
received desvenlafaxine 100 mg/day, 150 mg/day, or placebo 
for 12 weeks.63 In another trial conducted by Archer and 
colleagues, 458 postmenopausal women were assigned to 
desvenlafaxine 100 mg/day, 150 mg/day, or placebo for 
12 weeks.64 Finally, in a trial conducted by Bouchard and 
colleagues, 485 women received desvenlafaxine 100 mg/day, 
tibolone 2.5 mg/day, or placebo for 12 weeks.65 The inclusion 
and exclusion criteria of the four trials were similar. Women 
must have been postmenopausal, generally healthy, have a 
BMI , 40 kg/m2 (,34 kg/m2 for the Bouchard et al trial65), 
and have reported a specific quantity of moderate to severe 
hot flashes (seven per day or 50 per week). Women who 
had recently received hormone therapy or any medications 
thought to treat VMS, having a history of seizure disorder, 
myocardial infarction, or malignancy, or having hepatic 
dysfunction, renal dysfunction, a psychiatric disorder, or any 
other major medical disease were excluded. No significant 
differences were observed between the treatment groups 
with regard to the baseline demographics in these trials. The 
majority of patients in each of these trials were of Caucasian 
descent (80%–90%). Table 3 describes the design, primary 
and secondary end points, and results for each of these 
clinical trials.
Efficacy results – primary end points
The four clinical trials evaluating desvenlafaxine for the 
treatment of menopause-related VMS used two common 
primary end points: the change in the daily frequency of 
moderate-to-severe hot flashes and the change in the daily 
average hot-flash severity score.62–65 In three of the trials, 
the change in the daily average hot-flash severity score was 
calculated as: ([number of mild hot flashes × 1] + [number 
of moderate not flashes × 2] + [number of severe hot 
flashes × 3])/total number of hot flashes on that day.62,63,65 
In the fourth clinical trial, the procedure for calculating 
the average daily hot-flash severity score was not clearly 
defined.64
In both studies conducted by Archer and colleagues, 
the 100-mg/day and 150-mg/day doses of desvenlafaxine 
were superior to placebo at reducing the number of 
moderate-to-severe hot flashes at weeks 4 and 12.63,64 In 
these two studies, both desvenlafaxine groups experienced 
a reduction in the frequency of moderate-to-severe hot 
flashes by 60%–66%. In one Archer trial, the desvenlafaxine 
100-mg group and 150-mg group differed significantly from 
placebo at weeks 4 and 12 (P , 0.002 at week 4 for both 
groups; P , 0.001 at week 12 for both groups).63 In the other 
Archer trial, the desvenlafaxine 100-mg group and 150-mg 
group also differed significantly from placebo at weeks 4 
and 12 (P # 0.012 for both groups at week 4, P , 0.005 for 
the 100-mg group, and P , 0.012 for the 150-mg group at 
week 12).64 In the trial conducted by Speroff and colleagues, 
desvenlafaxine doses of 100 mg/day and 150 mg/day sig-
nificantly reduced the average daily number of moderate-
to-severe hot flashes compared with placebo at week 12 
by 60%–64% (P = 0.005 and P = 0.02, respectively).62 
However, in this trial, the results for the desvenlafaxine 
150-mg group did not differ significantly from placebo at 
week 4, and the desvenlafaxine 50-mg and 200-mg groups 
did not differ significantly from placebo at either week 4 or 
12. In contrast, Bouchard and colleagues observed that the 
average daily number of moderate-to-severe hot flashes was 
not significantly different for the desvenlafaxine group at 
weeks 4 and 12 compared to placebo: desvenlafaxine reduced 
the average number of hot flashes by 57.7%, while placebo 
reduced the average number of hot flashes by 57.5% at week 
12.65 Tibolone reduced the average number of hot flashes by 
81% and differed significantly from placebo at weeks 4 and 
12 (P , 0.001 for all comparisons).65
In both studies by Archer and colleagues, the average 
daily hot-flash severity score differed significantly for both 
the desvenlafaxine 100-mg and 150-mg groups compared to 
placebo at weeks 4 and 12 (P # 0.005 at both time points;63 
P # 0.025 at both time points64). In the study by Speroff and 
colleagues, the 100-mg and 200-mg desvenlafaxine groups 
differed from placebo at week 12 in terms of the average 
daily severity score (P = 0.002 and P = 0.013, respectively), 
but not at week 4.62 However, the desvenlafaxine 50-mg and 
150-mg groups were not significantly different from placebo 
at week 4 or 12. In the study by Bouchard and colleagues, the 
average daily hot-flash severity score was not significantly 
different between the desvenlafaxine 100-mg group and 
placebo groups at weeks 4 and 12; however, the tibolone 
2.5-mg group was significantly different from placebo at both 
of these time points (P , 0.001 for both comparisons).65
Efficacy results – secondary endpoints
Important secondary endpoints of the trials included the 
proportion of patients achieving a 50% and 75% reduction 
in the number of hot flashes and the number of nighttime 
awakenings attributed to hot flashes.
The proportion of patients achieving at least a 50% 
or 75% reduction in the number of hot flashes was 
significantly different between placebo and the 100-mg 
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and 150-mg desvenlafaxine groups at weeks 4 and 12 in 
both trials  conducted by Archer and colleagues (P , 0.001 
for all comparisons in one Archer trial;63 P # 0.004 for 
all  comparisons in the other Archer trial64). Speroff and 
colleagues observed a significantly greater proportion of 
patients achieving a 75% or greater reduction compared with 
the placebo at week 4 in the desvenlafaxine 100-mg, 150-mg, 
and 200-mg groups (P = 0.005, P = 0.003, and P = 0.021, 
respectively).62 At week 12, only the 100-mg and 200-mg 
desvenlafaxine groups had significantly greater proportions 
of patients achieving a 75% reduction in the number of hot 
flashes (P = 0.003 and P = 0.022, respectively).62 There was 
no significant difference between the 50-mg desvenlafaxine 
group and placebo with regard to this particular end point 
at week 4 or 12. The results and statistics for the 50% 
reduction were not reported in the trial. In the trial conducted 
by Bouchard and colleagues, there was no significant 
difference between the 100-mg desvenlafaxine group and 
placebo in the proportion of patients achieving at least a 
50% or 75% reduction in the number of hot flashes at either 
week 4 or 12, but there was a significant difference between 
the 2.5-mg tibolone group and placebo (P , 0.001 for all 
comparisons).65
The number of nighttime awakenings attributed to hot 
flashes was significantly reduced in the desvenlafaxine 
100-mg and 150-mg groups compared to placebo at weeks 
4 and 12 in both trials by Archer and colleagues (P , 0.026 
and P , 0.001 at week 4 and 12;63 P , 0.04864). Speroff and 
colleagues found that this end point was significantly reduced 
in the desvenlafaxine 100-mg, 150-mg, and 200-mg groups 
compared to placebo at week 12 (P = 0.013, P = 0.034, and 
P = 0.043, respectively).62 No significant difference in this 
end point was observed between the desvenlafaxine 50-mg 
group and placebo at week 12. The results for this end point 
at week 4 were not reported in this trial. This end point 
was not evaluated in the trial conducted by Bouchard and 
colleagues.65
Safety and tolerability
The rates of treatment-emergent adverse effects and 
discontinuation were also evaluated in the four desvenlafaxine 
clinical trials. The most commonly observed adverse event 
in the desvenlafaxine treatment groups in all of these trials 
was nausea.
The study by Speroff and colleagues found that women 
receiving desvenlafaxine 150 mg or 200 mg experienced 
significantly more treatment-emergent adverse events 
(P = 0.04 and P = 0.006, respectively) than women in Ta
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the placebo group, while treatment-emergent adverse 
events did not differ significantly from placebo in the 
desvenlafaxine 50-mg and 100-mg groups.62 The incidence 
of nausea in the trial was around 40%–45% depending 
on the dose of desvenlafaxine. Discontinuations due to 
adverse events occurred at significantly higher rates in 
both the 150-mg and 200-mg desvenlafaxine groups (35% 
and 40%, respectively) compared with placebo (both 
comparisons, P , 0.001), while the rate of discontinuation 
in the desvenlafaxine 50-mg and 100-mg groups did not 
significantly differ from that associated with placebo.62
In one of the trials by Archer and colleagues, significantly 
more desvenlafaxine-treated subjects reported treatment-
emergent adverse events during week 1 compared to placebo 
(P , 0.05); however, no significant differences between these 
two groups were observed at any other time point regarding 
this outcome.63 Around 45% of all patients randomized to 
desvenlafaxine reported nausea during the trial. Significantly 
more patients in the desvenlafaxine groups (26.9% in the 
150-mg group; 30.2% in the 200-mg group) discontinued 
therapy due to treatment-emergent adverse events compared to 
placebo (8.9%; P , 0.001 for either treatment compared to 
placebo). In the second trial by Archer and colleagues, 
84.1% of the patients treated with desvenlafaxine reported 
treatment-emergent adverse events compared with 69.5% 
of patients in the placebo group (P , 0.002).64 In this trial 
25.5% of women treated with desvenlafaxine reported nausea 
during treatment. There were no significant differences in the 
rates of discontinuation of treatment for any reason, including 
adverse events, between the desvenlafaxine 100-mg (12.7%), 
150-mg (16.6%), and placebo groups (9.9%).
The incidence of uterine bleeding was the primary 
safety end point in the study conducted by Bouchard 
and colleagues.65 This endpoint was chosen because the 
comparator drug, tibolone, is a hormonal treatment known to 
cause uterine bleeding. The incidence of uterine bleeding was 
significantly higher in the tibolone group (23%) compared to 
both the desvenlafaxine and placebo groups (12%, P = 0.024, 
and 9%, P = 0.001, respectively).65 Treatment-emergent 
adverse events were reported among 73.4% of patients in 
the 100-mg desvenlafaxine group, 64.5% of patients in the 
tibolone group, and 55.9% of patients in the placebo group 
(P # 0.006 for placebo vs the tibolone and desvenlafaxine 
groups). Nausea was reported in 8.9% and ,4% of patients 
in the desvenlafaxine and placebo groups, respectively 
(P , 0.001). During the first week of treatment, the rate 
of drug discontinuation was significantly higher in the 
desvenlafaxine group (11%) than in the tibolone (1.8%) 
or placebo (1.6%) groups (P , 0.001 for desvenlafaxine 
vs the tibolone and placebo groups). The rate of drug 
discontinuation was not significantly different between the 
treatment groups at any other time point.
Discussion
VMS are a disturbing part of menopause for many women 
and have a significant impact on QOL. Although hormone 
therapy is the most effective treatment for menopause-related 
VMS, many women either cannot or do not wish to take this 
treatment. Therefore, the availability of effective alternative 
therapies for the treatment of VMS is of great importance. 
Desvenlafaxine, an SNRI, is one such treatment option for 
the treatment of VMS in postmenopausal women.
The desvenlafaxine trials published to date have incon-
sistent efficacy results. Both trials conducted by Archer and 
colleagues found desvenlafaxine to be more beneficial than 
placebo in treating VMS in terms of reducing the frequency 
of moderate-to-severe hot flashes, reducing the average daily 
hot-flash severity score, and reducing nighttime awakenings 
at doses of 100 mg and 150 mg.63,64 Speroff and colleagues 
also showed desvenlafaxine to be favorable in treating VMS; 
however, this trial had some confounding results as not all 
of the doses were superior to placebo at all identified time 
points.62 Further, while both studies conducted by Archer 
and the study conducted by Speroff noted the measurement 
of QOL within their research methods, this data has yet to 
be made available.62,64 Knowing the link between VMS and 
QOL,3,5 the lack of such data is significant. Lastly, Bouchard 
and colleagues observed no significant difference between the 
desvenlafaxine and placebo groups with regards to the reduc-
tion in the number of moderate-to-severe hot flashes, hot-
flash severity score, or number of nighttime awakenings.65
Several variables may contribute to the difference in 
efficacy rates observed in the trials. One important factor 
may be dose titration. Only the one study by Archer and 
colleagues64 titrated the dose of desvenlafaxine (starting all 
patients on 50 mg/day for at least 3 days, then increasing to 
100 mg/day, and finally 150 mg/day over 1 week), while 
in the other studies patients were started initially on the 
dose they were randomized to receive (100 mg, 150 mg, 
or 200 mg).62,64,65 Patients not titrated on SNRIs are more 
likely to experience adverse effects, in particular nausea.66 
As reported, in three of the four clinical trials presented,62,63,65 
discontinuation of therapy due to adverse events occurred at 
significantly higher rates in the desvenlafaxine-treated groups 
compared to the placebo group. No significant difference in 
the rate of treatment discontinuation was observed in only one 
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of the clinical trials.64 This particular trial was the only one to 
titrate the dose of desvenlafaxine over a week. Further, as all 
four of these trials used a modified intention-to-treat analysis, 
having more women discontinuing therapy due to adverse 
effects could make the desvenlafaxine look less desirable 
as a treatment option due to safety. In fact, Gallagher and 
colleagues conducted a study to look at how titrating the 
desvenlafaxine dose affects patient tolerability.66 In this 
study, patients were randomized to receive desvenlafaxine for 
7 days at the following doses: 100 mg/day (with no titration); 
50 mg/day (with no titration); 25 mg/day for 4 days titrated 
to 50 mg/day for 3 days; or 25 mg/day (with no titration). All 
patients subsequently received desvenlafaxine 100 mg/day 
for 15 weeks. Patients titrated to desvenlafaxine 100 mg 
experienced significantly less nausea (19%–25%) than the 
desvenlafaxine 100-mg group, whose dose was not titrated 
(35.2%; P , 0.05). The results of this study suggest that 
desvenlafaxine should be titrated to avoid unnecessary 
adverse effects that may lead to discontinuation of therapy. 
With early discontinuation, the full, potential efficacy of the 
medication is not able to be properly evaluated.
Another potential factor contributing to the variability 
of the outcomes in these studies is the population of women 
included in the analyses. Severity of VMS varies according 
to time since the onset of menopause.3,4 Symptoms are most 
severe in the 1–4 years surrounding the FMP, with symptoms 
improving the farther the woman is from her FMP. While the 
inclusion criteria for the clinical trials were generally similar 
relative to the frequency and severity of VMS in the included 
women,62–65 and the average age of the women was similar, 
the age ranges and specifics of the FMP of these women 
were quite variable. In both studies by Archer and colleagues, 
the average age in each of the trials was 53 years.63,64 In 
one of the trials, the ages of the women ranged from 29 to 
71 years,64 although the distribution was not reported. The 
age distribution was not reported in the other Archer study 
either.63 Similarly, in the Speroff et al trial, the average age 
was also 53 years; however, the ages ranged from 37 to 78 
years old.62 Again, the age distribution was not reported in 
this study. Bouchard and colleagues included postmenopausal 
women with an average age of 53 years.65 As with the other 
desvenlafaxine trials, no age distribution was reported.
Although the average age of women studied in all of the 
trials was approximately 53 years, a prominent time for the 
occurrence of VMS, the age ranges reported were quite vast, 
with women as young as 29 years and as old as 78 years 
being included.62–65 In particular, for the women of younger 
ages, whether or not their menopause was surgical was not 
reported. It is known that women who enter menopause 
due to surgery tend to experience more severe VMS.3 For 
reasons such as this, it would be very helpful to know the 
percentages of women within the various age ranges in the 
trials. Further, it would be helpful to know how many women 
were surgically menopausal versus naturally menopausal 
in the 1–4 years since their FMP versus 8 or more years 
 postmenopause. The inclusion of women with widely vari-
able time durations since their FMP may not be prudent to 
truly evaluate the effects of medications on VMS. Knowledge 
of this information may help to determine whether the symp-
tom improvement observed was secondary to drug treatment 
or to the length of time since their FMP. Such variability 
in the age ranges included in the studies may have been a 
contributor to the variable findings observed.
Additionally, the trials lacked reporting other information 
that would be of value in interpreting the trial results and in 
making clinical recommendations. Important information not 
reported in these trials relates to the proposed risk factors for 
VMS. One such determinant, as previously noted, includes 
whether or not the women had tried another form of therapy 
(hormone therapy, nonhormone therapy, vitamins/herbals, 
or even nonpharmacologic) in the past.8 Given the proven 
response rates to hormone therapy for VMS,36 women who 
had previously been on hormone therapy may have been more 
likely to report an inadequate response to desvenlafaxine 
in comparison to women who had never tried any kind of 
therapy before. Although part of the exclusion criteria in 
the trials was that women could not have been taking any 
hormone therapy or other medications used for the treatment 
of VMS within a certain time period before the trial, there 
was no specific mention of herbals and vitamins as part of 
this exclusion criteria. As many people do not consider these 
entities as “medications,” the reporting regarding taking these 
supplements may be inaccurate. If many women were taking 
herbals and vitamins to treat hot flashes during the studies, 
this would also be considered a confounding variable.
An interesting factor that may have impacted the results 
in all of these trials was the placebo effect. In both studies by 
Archer et al and the study by Speroff et al, the placebo caused 
a reduction in moderate-to-severe daily hot flashes by about 
50%.62–64 In the Bouchard et al study, placebo caused a 57.5% 
reduction in daily hot flashes.65 The reason for the large placebo 
effect seen in these trials is unknown. Perhaps it could be related 
to the natural course of the VMS and the age of the women (of 
note, this is another instance where the distribution of the ages 
of the women included would be useful); that is, perhaps certain 
women experienced a natural course of reduction in their VMS 
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over time. It may also be an indication of the subjective nature 
relative to the perception of VMS.
Other limitations of the trials include the study duration, 
the lack of ethnic diversity, and neglecting to evaluate the 
presence of VMS risk factors among the study participants. 
The efficacy endpoints used in all of the trials were evalu-
ated at 12 weeks, which is a rather short duration. As VMS 
are known to last for many years following the FMP,4 longer 
trials evaluating the efficacy and safety of desvenlafaxine 
over an extended time are warranted. Finally, as previously 
mentioned, over 80% of the patients in all of the trials were 
Caucasian. This significantly limits the generalizability of 
these study findings to other races and ethnicities.
Conclusion
Upon evaluation of the four clinical trials, the results 
demonstrate that desvenlafaxine is a viable option for the 
treatment of VMS in postmenopausal women. The results 
have shown that desvenlafaxine at doses of 100 mg or 
higher reduces the frequency of moderate-to-severe hot 
flashes and the number of nighttime awakenings. Further, 
doses of 100 mg have not been shown to cause significant 
side effects, as the incidence of treatment-emergent side 
effects with this dose is comparable to that observed with 
placebo.62 However, while it is a viable option in comparison 
to other therapies, desvenlafaxine cannot be recommended 
over the other available treatments. Studies comparing 
desvenlafaxine to other available treatment options relative 
to efficacy and safety are lacking, with the exception of the 
one trial comparing it to tibolone.65 The lack of head-to-head 
trials with the nonhormonal treatments, in particular, leave 
practitioners with numerous choices, as one medication has 
not been shown to be superior. Clinical trials comparing 
desvenlafaxine to other nonhormonal treatments are needed 
to establish its place relative to these other options. Larger 
studies with longer durations, inclusive of more diversity 
among subject ethnicity, and with a focus that includes 
reporting the impact on overall QOL, are warranted to 
evaluate the long-term safety and efficacy of desvenlafaxine 
for VMS treatment and improve the generalizability of 
the results. Finally, clinical trials evaluating desvenlafaxine 
should titrate the dose appropriately to minimize the chance 
of treatment discontinuation, and a more distinct study 
population should be used that more closely reflects the 
typical time frame of when VMS are most severe in relation 
to menopause. At this time, desvenlafaxine is a reasonable 
option for the treatment of VMS; however, more research is 
necessary to define its place in therapy.
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